These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2717660)

  • 1. Computerized documentation for lithium outpatients (routine and research data).
    Simhandl C; Thau K; Wolf R; Lenz G; Lovrek A; Wancata J; Topitz A; Denk E
    Pharmacopsychiatry; 1989 Mar; 22(2):76-80. PubMed ID: 2717660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
    Dardennes R; Lafuma A; Watkins S
    Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing lithium treatment.
    Dunner DL
    J Clin Psychiatry; 2000; 61 Suppl 9():76-81. PubMed ID: 10826665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
    Roick C; Ahrens B; Becker T
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of compliance with lithium and carbamazepine regimens in the long-term treatment of recurrent mood and related psychotic disorders.
    Lenzi A; Lazzerini F; Placidi GF; Cassano GB; Akiskal HS
    Pharmacopsychiatry; 1989 Jan; 22(1):34-7. PubMed ID: 2652160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of affective disorders.
    Alexander B; Cook B
    Prim Care; 1990 Sep; 17(3):565-88. PubMed ID: 2236337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders.
    Fritze J; Beneke M; Lanczik M; Schneider B; Walden J
    Pharmacopsychiatry; 1994 Sep; 27(5):181-5. PubMed ID: 7838887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative approaches to refractory depression in bipolar illness.
    Post RM; Leverich GS; Denicoff KD; Frye MA; Kimbrell TA; Dunn R
    Depress Anxiety; 1997; 5(4):175-89. PubMed ID: 9338110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow-release lithium in treatment of schizoaffective syndromes.
    Romeo R; Bastianello S; Janiri L; Mauro P; Pirrongelli C
    Int J Clin Pharmacol Res; 1985; 5(3):205-11. PubMed ID: 4018956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
    Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical predictors of long-term outcome of lithium prophylaxis in bipolar disorder].
    Garcia-López A; Ezquiaga E; Nieves P; Rodríguez-Salvanés F
    Actas Esp Psiquiatr; 2001; 29(5):327-32. PubMed ID: 11602090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The use of carbamazepine in affective disorders].
    Beresewicz M
    Psychiatr Pol; 1994; 28(4):455-66. PubMed ID: 7972553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
    Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
    J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality studies and the effectiveness of drugs in long-term treatment.
    Ahrens B
    Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):57-61. PubMed ID: 9035229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predictors of prophylactic response to lithium].
    Rohayem J; Baylé JF; Richa S
    Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients.
    Placidi GF; Lenzi A; Lazzerini F; Cassano GB; Akiskal HS
    J Clin Psychiatry; 1986 Oct; 47(10):490-4. PubMed ID: 3093468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards defining adequate lithium trials for individuals with mental retardation and mental illness.
    Pary RJ
    Am J Ment Retard; 1991 May; 95(6):681-91. PubMed ID: 2059418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrooculography and dark adaptation in patients with affective and schizoaffective psychoses: early physiological effects of carbamazepine and lithium.
    Kaschka WP; Thürauf N; Mokrusch T; Korth M
    Pharmacopsychiatry; 1988 Nov; 21(6):404-6. PubMed ID: 3244776
    [No Abstract]   [Full Text] [Related]  

  • 20. Mortality in 497 patients with affective disorders attending a lithium clinic or after having left it.
    Kallner G; Lindelius R; Petterson U; Stockman O; Tham A
    Pharmacopsychiatry; 2000 Jan; 33(1):8-13. PubMed ID: 10721878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.